Johnson & Johnson Neuro Drug Programs Boost Diagnostics Development
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is ramping up efforts to validate new diagnostics as companions to its neurological-focused drug development efforts.
You may also be interested in...
New J&J Drug Candidates Don't Go It Alone: Companion Dx Are Standard
Johnson & Johnson's drug business could be a particularly productive partnering site for molecular diagnostics firms over the next several years, statements from one company executive suggest
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.